Literature DB >> 26010766

Glucose regulates heat shock factor 1 transcription activity via mTOR pathway in HCC cell lines.

Wanli Ma1, Yaqing Zhang2, Hongmei Mu3, Xiaoming Qing2, Shulian Li2, Xiukun Cui2, Qiang Lou2, Yuanfang Ma2, Hongmin Pu4, Yanzhong Hu2.   

Abstract

HSF1-mediated heat shock response is activated in most tumors and plays important roles in regulating tumor homeostasis. However, the signals underlying HSF1 activation is still not completely understood. In this paper, we find that glucose, the dominant tumor energy supplement, participates in regulating HSF1's activation in HCC cell lines. The immunoblotting results indicate that the phosphorylation of HSF1/S326, a hallmark of HSF1 activation, varies between the HCC cell lines (e.g., SMMC7721, HapG2, plc/prf5, and Chang-liver). Glucose, but not 2D-glucose, can induce the phosphorylation of HSF1 at S326 and upregulate the expression of HSF1's downstream alpha B-crystallin and Hsp70 as well as the none-heat shock proteins CSK2 and RBM23 in two tested hepatocellular carcinoma cell lines (prl/prf5 and SMMC7721). Rapamycin, an inhibitor of mTOR, can suppress the glucose-induced phosphorylation of HSF1/S326 and the expression of alpha B-crystallin. Knockdown of HSF1 with shRNA enhances the glucose-depletion-mediated inhibition of plc/prf5 cell proliferation. Our data reveal that HSF1 can be activated by glucose-mTOR pathway, providing an alternative pathway for targeting HSF1 in tumor therapy.
© 2015 International Federation for Cell Biology.

Entities:  

Keywords:  HSF1; glucose; mTOR; phosphorylation and hepatocellular carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26010766     DOI: 10.1002/cbin.10493

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  9 in total

Review 1.  Exercise, heat shock proteins and insulin resistance.

Authors:  Ashley E Archer; Alex T Von Schulze; Paige C Geiger
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-19       Impact factor: 6.237

Review 2.  HSF1 as a Cancer Biomarker and Therapeutic Target.

Authors:  Richard L Carpenter; Yesim Gökmen-Polar
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

3.  MiRNA-671-5p Promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis.

Authors:  Zhiguo Zhu; Lianmin Luo; Qian Xiang; Jiamin Wang; Yangzhou Liu; Yihan Deng; Zhigang Zhao
Journal:  Cell Death Dis       Date:  2020-11-03       Impact factor: 8.469

4.  Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis.

Authors:  Antonio Cigliano; Maria G Pilo; Lei Li; Gavinella Latte; Marta Szydlowska; Maria M Simile; Panagiotis Paliogiannis; Li Che; Giovanni M Pes; Giuseppe Palmieri; Maria C Sini; Antonio Cossu; Alberto Porcu; Gianpaolo Vidili; Maria A Seddaiu; Rosa M Pascale; Silvia Ribback; Frank Dombrowski; Xin Chen; Diego F Calvisi
Journal:  Oncotarget       Date:  2017-10-03

Review 5.  Molecular Mechanisms of Heat Shock Factors in Cancer.

Authors:  Mikael Christer Puustinen; Lea Sistonen
Journal:  Cells       Date:  2020-05-12       Impact factor: 6.600

6.  Matrine Protects Against MCD-Induced Development of NASH via Upregulating HSP72 and Downregulating mTOR in a Manner Distinctive From Metformin.

Authors:  Ali Mahzari; Songpei Li; Xiu Zhou; Dongli Li; Sherouk Fouda; Majid Alhomrani; Wala Alzahrani; Stephen R Robinson; Ji-Ming Ye
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

7.  Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice.

Authors:  Antonio Cigliano; Chunmei Wang; Maria G Pilo; Marta Szydlowska; Stefania Brozzetti; Gavinella Latte; Giovanni M Pes; Rosa M Pascale; Maria A Seddaiu; Gianpaolo Vidili; Silvia Ribback; Frank Dombrowski; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Oncotarget       Date:  2017-04-07

8.  Fibronectin is a stress responsive gene regulated by HSF1 in response to geldanamycin.

Authors:  Karim Colin Hassan Dhanani; William John Samson; Adrienne Lesley Edkins
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

9.  The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.

Authors:  Cheng-Chan Yu; Sung-Ying Huang; Shu-Fang Chang; Kuan-Fu Liao; Sheng-Chun Chiu
Journal:  Molecules       Date:  2020-05-25       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.